1. Home
  2. KTTA vs IRIX Comparison

KTTA vs IRIX Comparison

Compare KTTA & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.46

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

HOLD

Current Price

$0.95

Market Cap

18.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTTA
IRIX
Founded
2020
1989
Country
United States
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
18.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
KTTA
IRIX
Price
$0.46
$0.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
570.7K
38.2K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
N/A
$41,593,000.00
Revenue This Year
N/A
$3.07
Revenue Next Year
N/A
$6.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.87
52 Week High
$2.06
$1.65

Technical Indicators

Market Signals
Indicator
KTTA
IRIX
Relative Strength Index (RSI) 29.39 24.95
Support Level $0.28 $0.87
Resistance Level $0.86 $1.21
Average True Range (ATR) 0.05 0.04
MACD -0.00 -0.02
Stochastic Oscillator 9.04 19.52

Price Performance

Historical Comparison
KTTA
IRIX

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About IRIX IRIDEX Corporation

IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Share on Social Networks: